drugset / Trial / NCT06948981
GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies
Phase 1/2
Recruiting
46 enrolled
Grit Biotechnology
Institute of Hematology & Blood Diseases Hospital, China · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is a prospective single-arm open-labled phase I/II clinical trial, including dose escalation and expansion phase, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in relapsed/refractory CD19 positive adult B-cell non Hodgkin lymphoma (B-NHL) and B-acute lymphoblastic leukemia (B-ALL) patients. A total of 46 subjects (anticipated) will be enrolled in this study.
Timeline
- Start
- 2025-04-18
- Primary completion
- 2028-04-17
- Completion
- 2028-04-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GT719 | Cell therapy | — | — |